The founder and chairwoman, Dominique Costantini, shares the company's purpose: "We have a passion for innovation and develop first-in-class immunotherapies". Discover in this video, the short- and medium-term objectives of OSE Immunotherapeutics for 2023.

Nicolas Poirier, CEO, presents the product portfolio with a focus on most advanced clinical programmes: "We have developed a rich and diversified product portfolio, with a strategy based on the development of assets in-house to create more value and on strategic quality partnerships".